April 22, 2026

Tzield Approval Expands to Younger Patients

First disease-modifying option available for children as young as 1 year with stage 2 type 1 diabetes

Conexiant

April 21, 2026

Two-Drug HIV Regimen Gains FDA Approval

Phase 3 trials showed noninferior viral suppression vs standard three-drug therapy with similar safety outcomes

Conexiant

April 20, 2026

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Conexiant

April 09, 2026

Marriage as a Marker of Cancer Risk?

Never-married adults show markedly higher cancer incidence. A large population study asks why marital status remains a footnote in risk frameworks.

Conexiant

April 08, 2026

FDA Clears At-Home HPV Screening Tool

Self-collection approach aims to expand screening access

Conexiant

April 02, 2026

CDC Lists Dozens of Infectious Disease Tests as Unavailable

More than two dozen assays paused or discontinued, with alternative testing options noted

Conexiant

April 02, 2026

Genomic Data Tracks Measles Spread

CDC sequencing may determine if endemic transmission has returned.

KFF Health News

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 27, 2026

FDA Approves Gene Therapy for Severe Pediatric LAD-I

Approval expands treatment option for a rare pediatric immunodeficiency

Conexiant

March 25, 2026

CDC Cuts: Fallout Hits Workforce

Mass layoffs, funding cuts, and violence disrupt CDC operations, raising concerns about long-term public health capacity.

KFF Health News